Zoetis Inc (ZTS)
153.36
+2.48
(+1.64%)
USD |
NYSE |
Apr 25, 16:00
155.10
+1.74
(+1.13%)
Pre-Market: 05:37
Zoetis Enterprise Value: 74.74B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 74.74B |
| April 24, 2024 | 73.60B |
| April 23, 2024 | 73.00B |
| April 22, 2024 | 71.16B |
| April 19, 2024 | 71.60B |
| April 18, 2024 | 74.63B |
| April 17, 2024 | 74.09B |
| April 16, 2024 | 74.58B |
| April 15, 2024 | 73.10B |
| April 12, 2024 | 73.19B |
| April 11, 2024 | 79.03B |
| April 10, 2024 | 79.25B |
| April 09, 2024 | 81.05B |
| April 08, 2024 | 80.39B |
| April 05, 2024 | 80.46B |
| April 04, 2024 | 80.31B |
| April 03, 2024 | 79.14B |
| April 02, 2024 | 80.07B |
| April 01, 2024 | 80.99B |
| March 28, 2024 | 82.00B |
| March 27, 2024 | 81.68B |
| March 26, 2024 | 80.38B |
| March 25, 2024 | 81.36B |
| March 22, 2024 | 81.86B |
| March 21, 2024 | 81.59B |
| Date | Value |
|---|---|
| March 20, 2024 | 82.81B |
| March 19, 2024 | 83.71B |
| March 18, 2024 | 82.68B |
| March 15, 2024 | 83.54B |
| March 14, 2024 | 84.14B |
| March 13, 2024 | 85.21B |
| March 12, 2024 | 87.56B |
| March 11, 2024 | 88.54B |
| March 08, 2024 | 87.93B |
| March 07, 2024 | 87.63B |
| March 06, 2024 | 88.55B |
| March 05, 2024 | 89.33B |
| March 04, 2024 | 90.54B |
| March 01, 2024 | 91.89B |
| February 29, 2024 | 95.33B |
| February 28, 2024 | 96.07B |
| February 27, 2024 | 95.64B |
| February 26, 2024 | 94.74B |
| February 23, 2024 | 94.82B |
| February 22, 2024 | 94.57B |
| February 21, 2024 | 90.78B |
| February 20, 2024 | 89.94B |
| February 16, 2024 | 90.78B |
| February 15, 2024 | 91.36B |
| February 14, 2024 | 88.81B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
48.55B
Minimum
Mar 23 2020
120.20B
Maximum
Dec 29 2021
80.83B
Average
81.25B
Median
Jan 20 2021
Enterprise Value Benchmarks
| Biogen Inc | 34.94B |
| Eli Lilly and Co | 711.57B |
| Pfizer Inc | 201.07B |
| Abbott Laboratories | 193.05B |
| Bristol-Myers Squibb Co | 117.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 525.00M |
| Revenue (Quarterly) | 2.213B |
| Total Expenses (Quarterly) | 1.504B |
| EPS Diluted (Quarterly) | 1.14 |
| Gross Profit Margin (Quarterly) | 67.10% |
| Profit Margin (Quarterly) | 23.72% |
| Earnings Yield | 3.31% |
| Operating Earnings Yield | 4.33% |
| Normalized Earnings Yield | 3.349 |